<DOC>
	<DOCNO>NCT01299181</DOCNO>
	<brief_summary>The investigator hypothesise long term statin treatment improve patient ' symptom anti-inflammatory effect . The beneficial effect patient symptom ( cough , sputum volume , bacterial load , airway function , exercise tolerance , exacerbation frequency health relate quality life ) consequent reduce neutrophilic airway inflammation .</brief_summary>
	<brief_title>A Trial Atorvastatin Anti-Inflammatory Agent Non-Cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description>BACKGROUND AND RATIONAL FOR STUDY Bronchiectasis chronic debilitate respiratory condition . Patients suffer daily cough , excess sputum production recurrent chest infection inflame permanently damage airway . It common Scottish incidence 1 1,000 1 10,000 . Over 600 patient Edinburgh monitor secondary care . They frequently utilise primary secondary care resource consultation , A &amp; E attendances inpatient admission . The economic burden huge- hospital admission alone bronchiectasis cost NHS Lothian 1 million pound alone last year . LIMITATIONS OF TREATMENT There evidence base long term treatment currently available . Long term antibiotic feasible option , increase problem antimicrobial resistance side effect , particular Clostridium difficile methicillin resistant Staphylococcus aureus ( MRSA ) , international drive reduce antibiotic usage . There urgent need novel non antibiotic treatment . Statins potential new non antibiotic treatment bronchiectasis Excessive neutrophilic airway inflammation central feature bronchiectasis . This paradoxically promote bacterial colonisation perpetuates damage airway create vicious cycle bacterial colonisation inflammation.1-3 Statins show powerful anti-inflammatory effects.4-6 In animal model , statin reduce neutrophil recruitment inflame lung reduce protease activity.7 Statin treatment show reduce epithelial cell adherence invasion Streptococcus pneumoniae in-vitro suggest role statin prevent bacterial colonisation.8 In healthy control expose lipopolysaccharide induce acute lung inflammation , pre-treatment simvastatin reduce neutrophil accumulation lung inhibit production myeloperoxidase , tumour necrosis factor-alpha , matrix metalloproteinases C-reactive protein.9 There also increase neutrophil apoptosis , suggest statin may aid resolution inflammation airway.10 STUDY HYPOTHESIS The investigator hypothesise long term statin treatment improve patient ' symptom anti-inflammatory effect . The beneficial effect patient symptom ( cough , sputum volume , bacterial load , airway function , exercise tolerance , exacerbation frequency health relate quality life ) consequent reduce neutrophilic airway inflammation . Planned study - This randomised double blind placebo control trial ass efficacy atorvastatin therapy patient clinically significant bronchiectasis . - No study previously undertake ( PUBMED Search `` statin '' `` bronchiectasis '' 18 March 2010- relevant article ) . - This unique proof principle study assess new non antibiotic treatment could benefit patient clinically significant bronchiectasis , without side effect profile long term antibiotic . - Following proof principle study , investigator aim design large multi-centred study assess long term statins new treatment . References 1 . Stockley RA et al . Elastolytic activity sputum relation purulence lung function patient bronchiectasis . Thorax 1984 ; 39 ( 6 ) :408-413 . 2 . Hill AT et al . Association airway bacterial load marker airway inflammation patient stable chronic bronchitis . Am J Med 2000 ; 109 ( 4 ) :288-95 . 3 . Inflammation : two-edged swordâ€”the model bronchiectasis . Cole PJ . Eur J Respir Dis Suppl . 1986 ; 147:6-15 . 4 . Ridker PM et al . C-reactive protein level outcomes statin therapy . N Engl J Med 2005 ; 352:20-8 . 5 . Terblanche M et al . Statins Sepsis : multiple modification multiple level . Lancet Infect Dis . 2007 ; 7 ( 5 ) :358-368 . 6 . Vaughan CJ , Murphy MB , Buckley BM . Statins low cholesterol . Lancet 1996 ; 348:1079-82 . 7 . Fessler MB et al . A role HMG coenzyme A reductase pulmonary inflammation host defense . Am J Respir Crit Care Med 2005 ; 171:606-15 . 8 . Rosch JW et al . Statins protect fulminant pneumococcal infection cytolysin toxicity mouse model sickle cell disease . J Clin Invest 2010 ; 120 ( 2 ) ; 627-35 . 9 . Shyamsundar M et al . Simvastatin decrease lipopolysacchraide-induced pulmonary inflammation healthy volunteer . Am J Respir Crit Care Med . 2009 179:1107-1114 . 10 . Watt AP et al . Neutrophil apoptosis , proinflammatory mediator cell count bronchiectasis . Thorax 2004 ; 59 ( 3 ) :231-6 .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Patients age 1875 recruit . All establish radiological diagnosis bronchiectasis ( CT chest ) . Patients clinically significant bronchiectasis expectorate mucopurulent purulent sputum clinically stable least 2 chest infection per year . current smoker exsmokers less 1 year ; &gt; 15 pack year history cystic fibrosis active allergic bronchopulmonary aspergillosis active tuberculosis poorly control asthma pregnancy breast feed know allergy statin active malignancy chronic liver disease establish cardiovascular cerebrovascular disease statin use last year patient long term oral macrolides due interaction statin therapy patient chronically colonise Pseudomonas aeruginosa ( define two isolates Pseudomonas aeruginosa whilst clinically stable 6 month prior study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Bronchiectasis</keyword>
	<keyword>Outcome</keyword>
	<keyword>Statin therapy</keyword>
</DOC>